The Auto-Antibodies on Bone Marrow Cells in the Patients with Systemic Lupus Erythematosus.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3856-3856
Author(s):  
Rong Fu ◽  
Jizi Deng ◽  
Shang Yuan ◽  
Lu Gong ◽  
Jun Sun ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Bone Marrow ◽  
Lupus Erythematosus ◽  
Mononuclear Cells ◽  
Healthy Controls ◽  
Coombs Test ◽  
Systemic Lupus ◽  
Cell Counts ◽  
Significant Difference ◽  
Positive Rate

Abstract Objective:To explore the pathogenesis of cytopenia in the patients with systemic lupus erythematosus (SLE), the auto-antibodies on bone marrow mononuclear cells (BMMBC) in the patients with SLE were determined. Methods:Twenty one patients with SLE and ten healthy controls were enrolled in this study. BMMNC Coombs test was used to determine the aotoantibodies. The correlation between the types of auto-antibodies on BMMNC, the types of serum auto-antibodies and the counts of blood cells in the patients with SLE were also investigated. Results:Positive results of BMMBC-Coombs test were seen in 12 patients with SLE (57.1%), among them, 10 with hemocytopenia (58.82%), and 2 without hemocytopenia (50%). The positive rate of BMMNC Coombs test was higher in the patients with SLE than that in healthy controls, and was higher in SLE patients with hemocytopenia than that in healthy controls. There were no significant difference of BMMNC-Coombs positive rate between the SLE patients without hemocytopenia and healthy controls, and there were also no significant differences between the SLE patients without hemocytopenia and SLE patients with hemocytopenia. In the 12 SLE patients with positive BMMBC-Coombs tests, IgM auto-antibody accounted for 75.0%, and C3 50.0%, IgG 8.33%, IgG+IgM 8.33%, C3+IgM 16.67%, IgG+IgM+C3 16.67%. In the SLE patients without hemocytopenia, IgG+IgM accounted for 8.33%, C3 8.33%, but IgA autoantibody were not seen in any case. There was a significant positive correlation between the auto-antibodies on BMMNC and peripheral anti-SSA, but there was no significant correlation between the results of BMMBC Coombs tests and peripheral blood cell counts. Conclusion:There were auto-antibodies on BMMNC in the patients with SLE. The hemocytopenia in the patients with SLE maybe resulted from the destructions of bone marrow hematopoietic cells by the autoantibodies.

mRNA expression analysis confirms CD44 splicing impairment in systemic lupus erythematosus patients

Lupus ◽  
2021 ◽  
pp. 096120332110047
Author(s):  
Andrea Latini ◽  
Lucia Novelli ◽  
Fulvia Ceccarelli ◽  
Cristiana Barbati ◽  
Carlo Perricone ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
T Cells ◽  
Mrna Expression ◽  
Lupus Erythematosus ◽  
Mononuclear Cells ◽  
Direct Sequencing ◽  
Healthy Controls ◽  
Systemic Lupus ◽  
Peripheral Tissues ◽  
Variant Isoforms

Background Systemic Lupus Erythematosus (SLE) is a complex chronic autoimmune disease characterized by several immunological alterations. T cells have a peculiar role in SLE pathogenesis, moving from the bloodstream to the peripheral tissues, causing organ damage. This process is possible for their increased adherence and migration capacity mediated by adhesion molecules, such as CD44. Ten different variant isoforms of this molecule have been described, and two of them, CD44v3 and CD44v6 have been found to be increased on SLE T cells compared to healthy controls, being proposed as biomarkers of disease and disease activity. The process of alternative splicing of CD44 transcripts is not fully understood. We investigated the mRNA expression of CD44v3 and CD44v6 and also analyzed possible CD44 splicing regulators (ESRP1 molecule and rs9666607 CD44 polymorphism) in a cohort of SLE patients compared to healthy controls. Methods This study involved 18 SLE patients and 18 healthy controls. Total RNA and DNA were extracted by peripheral blood mononuclear cells. The expression study was conducted by quantitative RT-polymerase chain reaction, using SYBR Green protocol. Genotyping of rs9666607 SNP was performed by direct sequencing. Results CD44v6 mRNA expression was higher in SLE patients compared to healthy controls (p = 0.028). CD44v3/v6 mRNA ratio in healthy controls was strongly unbalanced towards isoform v3 compared to SLE patients (p = 0.002) and decreased progressively from healthy controls to the SLE patients in remission and those with active disease (p = 0.015). The expression levels of CD44v3 and CD44v6 mRNA correlated with the disease duration (p = 0.038, Pearson r = 0.493 and p = 0.038, Pearson r = 0.495, respectively). Splicing regulator ESRP1 expression positively correlated with CD44v6 expression in healthy controls (p = 0.02, Pearson r = 0.532) but not in SLE patients. The variant A allele of rs9666607 of CD44 was associated with higher level of global CD44 mRNA (p = 0.04) but not with the variant isoforms. Conclusions In SLE patients, the increase in CD44v6 protein correlates with a higher transcript level of this isoform, confirming an impairment of CD44 splicing in the disease, whose regulatory mechanisms require further investigation.

scholarly journals Cytokines in Systemic lupus erythematosus.

2020 ◽  
Author(s):  
Angel Alberto Justiz-Vaillant
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Pearson Correlation ◽  
Caribbean Region ◽  
Type I ◽  
Healthy Controls ◽  
Childbearing Age ◽  
Systemic Lupus ◽  
Sledai Score ◽  
Significant Difference

The systemic lupus erythematosus (SLE) is the greatest manifestation of autoimmunity. It is characterized by the presence of cytokines, including type I and II interferons, interleukin-6 (IL-6), IL-1, and tumor necrosis factor-alpha (TNF-α), the immunomodulatory cytokines like IL-10 and TGF-β, be essential players in SLE. Additionally, T-cell-derived cytokines like IL-17A, IL-21, and IL-2 are dysregulated in SLE. In this paper, a prospective cross-sectional and observational study was done. It was measured the levels of 3 essential cytokines in SLE: IL-17A, IL-23, and IL-33 using three enzyme-linked immunosorbent assays (ELISA). Thirty (30) patients attending the rheumatoid clinic at one of the major regional hospitals in the Caribbean region were recruited. Mostly females above the childbearing age give their consent to be included in the study and other 30 healthy patients were used a control. Of all the SLE patients, 15 (50%) patients were of Afro-Caribbean descent, 12 (40%) of patients were of Indo-Caribbean descent, and 3 (10%) of patients were of mixed descent. Nineteen (63%) healthy controls were females, and 11 (37%) were males. The results showed that serum IL-17A and IL-23 were more significantly higher in SLE patients than controls (P<0.01); however, there was no statistically significant difference between IL-33 levels between SLE patients and healthy controls. The study showed no correlation between serum IL-17A and IL-23 in SLE patients as judged by the result of the Pearson correlation coefficient (r=0.308, p>0.05). It also showed that serum IL-17A and IL-23 levels positively correlate to the SLE disease activity index 2000 score (SLEDAI score). Nevertheless, IL-33 levels show no correlation with the SLEDAI score. In this study, higher cytokines were reported mostly in patients between the ages of 25 to 30-year-old and Afro-Caribbean descent.

scholarly journals Upregulated PD-1 Expression Is Associated with the Development of Systemic Lupus Erythematosus, but Not the PD-1.1 Allele of the PDCD1 Gene

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Qingqing Jiao ◽  
Cuiping Liu ◽  
Ziliang Yang ◽  
Qiang Ding ◽  
Miaomiao Wang ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Mononuclear Cells ◽  
Activity Index ◽  
Disease Activity Index ◽  
Peripheral Tolerance ◽  
Systemic Lupus ◽  
Peripheral Blood Mononuclear ◽  
Expression Levels ◽  
Significant Difference

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with complicated genetic inheritance. Programmed death 1 (PD-1), a negative T cell regulator to maintain peripheral tolerance, induces negative signals to T cells during interaction with its ligands and is therefore a candidate gene in the development of SLE. In order to examine whether expression levels of PD-1 contribute to the pathogenesis of SLE, 30 patients with SLE and 30 controls were recruited and their PD-1 expression levels in peripheral blood mononuclear cells (PBMCs) were measured via flow cytometry and quantitative real-time-reverse transcription polymerase chain reaction (RT-PCR). Also, whether PD-1 expression levels are associated with the variant of the SNP rs36084323 and the SLE Disease Activity Index (SLEDAI) was studied in this work. The PD-1 expression levels of SLE patients were significantly increased compared with those of the healthy controls. The upregulated PD-1 expression levels in SLE patients were greatly associated with SLEDAI scores. No significant difference was found between PD-1 expression levels and SNP rs36084323. The results suggest that increased expression of PD-1 may correlate with the pathogenesis of SLE, upregulated PD-1 expression may be a biomarker for SLE diagnosis, and PD-1 inhibitor may be useful to SLE treatment.

scholarly journals Basophils as a potential marker of lupus nephritis by flow cytometry

2021 ◽  
pp. FSO690
Author(s):  
Yanni Jiang ◽  
Jin Chen ◽  
Yi Zhao ◽  
Yi Liu ◽  
Hong Xu ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Flow Cytometry ◽  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Mononuclear Cells ◽  
Lymphoid Cells ◽  
Healthy Controls ◽  
Systemic Lupus ◽  
Cross Sectional ◽  
Potential Marker

Objective: To establish a convenient and simple flow cytometry immunophenotyping panel to explore immune cellular alterations and potential cellular biomarkers in systemic lupus erythematosus. Materials and methods: This is a cross-sectional, case–control study including 60 patients with systemic lupus erythematosus and 20 sex- and age-matched healthy controls. A 14-color immunophenotyping panel was applied to detect proportions of circulating immune mononuclear cells, and comparisons between patients and healthy controls, and subgroups of patients, were performed. Correlations between cellular proportions and other parameters were investigated. Results: After multivariate analysis, significantly decreased proportions of CD4−CD8− T cells, natural killer cells and innate lymphoid cells were observed in patients compared with healthy controls. The proportions of basophils were decreased significantly in patients with lupus nephritis (LN) compared with those in patients without LN. Conclusion: In the present study, we found that basophil proportions may be a biomarker of LN.

scholarly journals POS0784 AUDIOLOGIC EVALUATION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AND IMPACT OF HYDROXYCHLOROQUINE THERAPY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 645.2-645
Author(s):  
S. Tharwat ◽  
W. Elshawaf ◽  
M. K. Nassar
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Hearing Impairment ◽  
Lupus Erythematosus ◽  
Chronic Administration ◽  
Healthy Controls ◽  
Systemic Lupus ◽  
High Frequency Audiometry ◽  
Significant Difference ◽  
Patient Reported ◽  
The Impact

Background:Hydroxychloroquine (HCQ) is a commonly used agent in the treatment of rheumatic diseases including systemic lupus erythematosus (SLE). [1]Objectives:The aim of this study was to evaluate the hearing function in SLE patients and assess the impact of chronic HCQ.Methods:This study was carried out on 60 individuals (48 SLE and 12 healthy controls). The SLE patients were divided into HCQ group (n=36) and non-HCQ group (n=12) according to the chronic administration of HCQ. All participants were assessed by full audiological history and extended high frequency audiometry at frequencies 9, 10, 11, 2, 12.5, 14, 16,18 and 20 KHz.Results:When comparing the study SLE patients with healthy controls,there was a statistically significant difference regarding patient reported otological manifestations such as tinnitus (p=.021), vertigo (p=.002) and hearing impairment (p=.042) while there was no significant difference regarding deafness or ear buzzing in one or both ears. HCQ group showed more hearing impairment at frequency 9000 and 20000 Hz than non-HCQ group (p=.004, <.001 respectively).Conclusion:Otological symptoms and sensorineural hearing loss are prevalent among SLE patients. Chronic administration of HCQ may have an ototoxic effect.References:[1]Fiehn, C., et al. “Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review.” Zeitschrift für Rheumatologie (2020): 1-9.Figure 1.Otological manifestations in the study SLE patients (n=48) and the healthy controls (n=12)Disclosure of Interests:None declared

Proliferative Function of Bone Marrow Hematopoietic Stem Cells of Patients with Systemic Lupus Erythematosus.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3857-3857
Author(s):  
Rong Fu ◽  
Jizi Deng ◽  
Shang Yuan ◽  
Lu Gong ◽  
Jun Sun ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Stem Cells ◽  
Bone Marrow ◽  
Hematopoietic Stem Cells ◽  
Lupus Erythematosus ◽  
Mononuclear Cells ◽  
Systemic Lupus ◽  
Hematopoietic Stem ◽  
Normal Controls

Abstract Objective:To investigate the bone marrow function of stem cells in patients with systemic lupus erythematosus (SLE), and to explore the pathogenesis of cytopenia in patients with SLE. Methods:Sixteen patients with SLE and 10 healthy controls were studied for in vitro cultures of CFU-E, BFU-E and CFU-GM from bone marrow mononuclear cells. Results:49.43±34.65 of CFU-E colonies per 105 BMMCs, 49.2±39.61 of CFU-GM colonies per 105 BMMNCs and 3.01±4.54 of BFU-E colonies per 105 BMMCs were seen in the group of SLE patients with normal blood count. 143.33±152.8 of CFU-E colonies per 105 BMMCs, 122.2±169.87 of CFU-GM colonies per 105 BMMCs, and 2.76±3.28 of BFU-E colonies per 105 BMMCs were seen in the group of SLE with hemocytopenia. 66.3±12.95 of CFU-E colonies per 105 BMMCs, 36.7±11.95 of CFU-GM colonies per 105 BMMCs, and 36±11.66 of BFU-E colonies per 105 BMMCs were seen in the group of normal controls.The quantity of BFU-E colonies per 105 BMMCs in SLE patients were significant lower than that in normal controls. There were no significant differences of the quantities of CFU-GM and CFU-E colonies between the SLE patients and normal controls. Conclusions: 1. There were no significant differences of CFU-GM and CFU-E colonies between the SLE patients and normal controls, that suggested that SLE patients have normal proliferate function of bone marrow hematopoietic stem cells.2 There were significant lower BFU-E colonies per 105 BMMCs in SLE patients than that in normal controls.

Circulating antioxidant levels in systemic lupus erythematosus patients: a systematic review and meta-analysis

2019 ◽  
Vol 13 (13) ◽  
pp. 1137-1152 ◽  
Author(s):  
Napoleon Bellua Sam ◽  
Bao-Zhu Li ◽  
Rui-Xue Leng ◽  
Hai-Feng Pan ◽  
Dong-Qing Ye
Keyword(s):  
Systematic Review ◽  
Systemic Lupus Erythematosus ◽  
Serum Level ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Meta Analysis ◽  
Healthy Controls ◽  
Systemic Lupus ◽  
Precise Estimation ◽  
Significant Difference

Aim: To derive a precise estimation on plasma/serum level of SOD, GPx, CAT and GSH levels in systemic lupus erythematosus (SLE) patients. Methods: A total of 36 articles from electronic databases were finally included with 1120 SLE patients and 1024 healthy controls considered for antioxidant levels. Results: The levels of CAT and GSH were significantly lower, while SOD and GPx levels were slightly lower in patients with SLE compared with healthy controls. Subgroup analysis indicated that Arabs, ages ≥40 and SLE diseases activity index <6 had a significant association of SOD and CAT levels with SLE patients. Conclusion: The results demonstrated a significant lower CAT and GSH levels and also revealed no significant difference for SOD and GPx levels in SLE patients.

Deregulated NLRP3 and NLRP1 Inflammasomes and Their Correlations with Disease Activity in Systemic Lupus Erythematosus

2013 ◽  
Vol 41 (3) ◽  
pp. 444-452 ◽  
Author(s):  
Qingrui Yang ◽  
Chengcheng Yu ◽  
Zhaowen Yang ◽  
Qing Wei ◽  
Kun Mu ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Mononuclear Cells ◽  
Activity Index ◽  
Type I ◽  
Healthy Controls ◽  
Systemic Lupus ◽  
Glucocorticoid Treatment ◽  
Peripheral Blood Mononuclear

Objective.NOD-like receptor family, pyrin domain containing 3 and 1 (NLRP3 and NLRP1) inflammasomes are molecular platforms that sense the damage or danger signals of cells. We investigated whether NLRP3/NLRP1 inflammasomes are involved in the pathogenesis and progression of systemic lupus erythematosus (SLE).Methods.Expressions of inflammasome components at the mRNA and protein levels in the peripheral blood mononuclear cells (PBMC) from patients with SLE and healthy controls were investigated by quantitative real-time transcription PCR and Western blot, respectively. Correlations between NLRP3/NLRP1 inflammasome components’ expression and clinical disease progression were investigated. Expressions of NLRP3/NLRP1 inflammasomes before and after treatment in the patients with SLE were also analyzed and compared.Results.Our data showed that expressions of NLRP3/NLRP1 inflammasomes were significantly downregulated in PBMC from patients with SLE compared with PBMC from healthy controls. Further, expressions of NLRP3/NLRP1 inflammasomes were negatively correlated with the SLE Disease Activity Index, and regular glucocorticoid treatment significantly corrected this deregulation of these inflammasomes. Further analysis showed that type I interferon (IFN) level was significantly negatively correlated with expression of NLRP3/NLRP1 inflammasomes, which indicated that enhanced IFN-I level in patients with SLE was responsible, at least to a great degree, for the deregulation of inflammasomes.Conclusion.These results indicated deregulation of NLRP3/NLRP1 inflammasomes in patients with SLE, and suggested an important role for inflammasomes in the pathogenesis and progression of SLE.

Sign in / Sign up

Export Citation Format

Share Document